The Leibniz Institute for Immunotherapy (LIT) is a research institute dedicated to the development of novel, curative immunotherapies for the treatment of cancer, chronic inflammation, and autoimmune disease. The Institute’s unique approach is to combine basic immunology and translational research to develop next-generation immune cell therapies. Current strategies focus on selecting optimal immune cell subsets and reprogramming cell function and differentiation using synthetic biology and gene-engineering approaches. The institute is equipped with modern infrastructures, including the José Carreras Center for Somatic Cell Therapy, a state-of-the-art facility that specializes in pharmaceutical development and GMP-compliant production of cell therapeutics.
Contact
Leibniz Institute for Immunotherapie
Franz-Josef-Strauß-Allee 11
93053 Regensburg
T +49 941 944 38100
info@rcii.de
Management

Director:
Prof. Philipp Beckhove

Administrative Director:
Brigitte Herbst

Press and Public Relations:
Federica Mennella